MULTI-CENTER TRIAL TO EVALUATE HOME-BASED ASSESSMENT METHODS FOR ALZHEIMER DISEA
评估阿尔茨海默病家庭评估方法的多中心试验
基本信息
- 批准号:7951076
- 负责人:
- 金额:$ 1.42万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2008
- 资助国家:美国
- 起止时间:2008-12-01 至 2009-11-30
- 项目状态:已结题
- 来源:
- 关键词:Alzheimer&aposs DiseaseClinicClinicalClinical ResearchClinical TrialsComputer Retrieval of Information on Scientific Projects DatabaseConduct Clinical TrialsDropsFundingGrantHealth ResourcesHome environmentImpaired cognitionIndividualInstitutionLeadMedicalMethodsPersonsPreventionResearchResearch PersonnelResourcesRiskSample SizeSiteSourceTimeTransportationUnited States National Institutes of HealthVisitbasecostprevent
项目摘要
This subproject is one of many research subprojects utilizing the
resources provided by a Center grant funded by NIH/NCRR. The subproject and
investigator (PI) may have received primary funding from another NIH source,
and thus could be represented in other CRISP entries. The institution listed is
for the Center, which is not necessarily the institution for the investigator.
There is an unmet need for effective, efficient and economical methods for conducting clinical trials to prevent Alzheimer s disease. Traditional in-person visits to a clinic are time consuming and costly and may exclude certain individuals from participation, such as those who are older, or are less mobile or who have significant medical illnesses. These may be the very people who are at greatest risk for cognitive decline, as well as those without financial resources for transportation to a study site. Prevention trials also require long observation periods and these same issues of health, resources, and transportation may cause significant drop out. These obstacles increase expense of clinical trials as they require large sample sizes, costly clinical staff and long observation periods. Thus, home-based assessments may lead to more representative recruitment of those most at risk for decline, better retention and reduced study costs.
这个子项目是许多研究子项目中的一个
由NIH/NCRR资助的中心赠款提供的资源。子项目和
研究者(PI)可能从另一个NIH来源获得了主要资金,
因此可以在其他CRISP条目中表示。所列机构为
研究中心,而研究中心不一定是研究者所在的机构。
对于用于进行预防阿尔茨海默病的临床试验的有效、高效和经济的方法存在未满足的需求。传统的亲自到诊所就诊既耗时又昂贵,并且可能将某些人排除在参与之外,例如年龄较大或移动的较少或患有严重疾病的人。这些人可能是认知能力下降风险最大的人,以及那些没有经济来源前往研究地点的人。 预防性试验也需要长时间的观察,这些同样的健康、资源和运输问题可能导致显著的脱落。这些障碍增加了临床试验的费用,因为它们需要大的样本量、昂贵的临床工作人员和长的观察期。因此,基于家庭的评估可能会导致更有代表性的招聘那些最有可能下降,更好地保留和减少研究费用。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
RUTH MULNARD MCCARGAR其他文献
RUTH MULNARD MCCARGAR的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('RUTH MULNARD MCCARGAR', 18)}}的其他基金
A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED TRIAL OF THE EFFECTS OF DOCOSAHEXAE
DOCOSAHEXAE 作用的随机双盲安慰剂对照试验
- 批准号:
8166913 - 财政年份:2009
- 资助金额:
$ 1.42万 - 项目类别:
MULTI-CENTER TRIAL TO EVALUATE HOME-BASED ASSESSMENT METHODS FOR ALZHEIMER DISEA
评估阿尔茨海默病家庭评估方法的多中心试验
- 批准号:
8166928 - 财政年份:2009
- 资助金额:
$ 1.42万 - 项目类别:
A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED TRIAL OF THE EFFECTS OF DOCOSAHEXAE
DOCOSAHEXAE 作用的随机双盲安慰剂对照试验
- 批准号:
7951056 - 财政年份:2008
- 资助金额:
$ 1.42万 - 项目类别:
CLINICAL TRIAL: PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLE
临床试验:第 3 阶段多中心、随机、双盲、安慰剂对照
- 批准号:
7725006 - 财政年份:2007
- 资助金额:
$ 1.42万 - 项目类别:
CLINICAL TRIAL: EVALUATION OF THE SAFETY, TOLERABILITY AND IMPACT ON BIOMARKERS
临床试验:评估安全性、耐受性和对生物标志物的影响
- 批准号:
7725024 - 财政年份:2007
- 资助金额:
$ 1.42万 - 项目类别:
A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED TRIAL OF THE EFFECTS OF DOCOSAHEXAE
DOCOSAHEXAE 作用的随机双盲安慰剂对照试验
- 批准号:
7725039 - 财政年份:2007
- 资助金额:
$ 1.42万 - 项目类别:
相似国自然基金
新型F-18标记香豆素衍生物PET探针的研制及靶向Alzheimer's Disease 斑块显像研究
- 批准号:81000622
- 批准年份:2010
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目
阿尔茨海默病(Alzheimer's disease,AD)动物模型构建的分子机理研究
- 批准号:31060293
- 批准年份:2010
- 资助金额:26.0 万元
- 项目类别:地区科学基金项目
跨膜转运蛋白21(TMP21)对引起阿尔茨海默病(Alzheimer'S Disease)的γ分泌酶的作用研究
- 批准号:30960334
- 批准年份:2009
- 资助金额:22.0 万元
- 项目类别:地区科学基金项目
相似海外基金
Pathophysiological mechanisms of hypoperfusion in mouse models of Alzheimer?s disease and small vessel disease
阿尔茨海默病和小血管疾病小鼠模型低灌注的病理生理机制
- 批准号:
10657993 - 财政年份:2023
- 资助金额:
$ 1.42万 - 项目类别:
Social Connectedness and Communication in Parents with Huntington''s Disease and their Offspring: Associations with Psychological and Disease Progression
患有亨廷顿病的父母及其后代的社会联系和沟通:与心理和疾病进展的关联
- 批准号:
10381163 - 财政年份:2022
- 资助金额:
$ 1.42万 - 项目类别:
The Role of Menopause-Driven DNA Damage and Epigenetic Dysregulation in Alzheimer s Disease
更年期驱动的 DNA 损伤和表观遗传失调在阿尔茨海默病中的作用
- 批准号:
10531959 - 财政年份:2022
- 资助金额:
$ 1.42万 - 项目类别:
The Role of Menopause-Driven DNA Damage and Epigenetic Dysregulation in Alzheimer s Disease
更年期驱动的 DNA 损伤和表观遗传失调在阿尔茨海默病中的作用
- 批准号:
10700991 - 财政年份:2022
- 资助金额:
$ 1.42万 - 项目类别:
Interneurons as early drivers of Huntington´s disease progression
中间神经元是亨廷顿病进展的早期驱动因素
- 批准号:
10518582 - 财政年份:2022
- 资助金额:
$ 1.42万 - 项目类别:
Interneurons as Early Drivers of Huntington´s Disease Progression
中间神经元是亨廷顿病进展的早期驱动因素
- 批准号:
10672973 - 财政年份:2022
- 资助金额:
$ 1.42万 - 项目类别:
Social Connectedness and Communication in Parents with Huntington''s Disease and their Offspring: Associations with Psychological and Disease Progression
患有亨廷顿病的父母及其后代的社会联系和沟通:与心理和疾病进展的关联
- 批准号:
10585925 - 财政年份:2022
- 资助金额:
$ 1.42万 - 项目类别:
Oligodendrocyte heterogeneity in Alzheimer' s disease
阿尔茨海默病中的少突胶质细胞异质性
- 批准号:
10180000 - 财政年份:2021
- 资助金额:
$ 1.42万 - 项目类别:
Serum proteome analysis of Alzheimer´s disease in a population-based longitudinal cohort study - the AGES Reykjavik study
基于人群的纵向队列研究中阿尔茨海默病的血清蛋白质组分析 - AGES 雷克雅未克研究
- 批准号:
10049426 - 财政年份:2021
- 资助金额:
$ 1.42万 - 项目类别:
Repurposing drugs for Alzheimer´s disease using a reverse translational approach
使用逆翻译方法重新利用治疗阿尔茨海默病的药物
- 批准号:
10295809 - 财政年份:2021
- 资助金额:
$ 1.42万 - 项目类别:














{{item.name}}会员




